Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Nuclea, WILEX ink share deal agreement
September 2013
SHARING OPTIONS:

PITTSFIELD, Mass.Nuclea Biotechnologies Inc. and WILEX AG have announced a share deal agreement under which Nuclea will acquire all shares of WILEX Inc., also known as Oncogene Science, a wholly owned U.S. subsidiary of WILEX AG. Per the terms, Nuclea will assume WILEX Inc.'s assets as well as assuming responsibility for repaying $2.5 million under an intercompany loan between WILEX Inc. and WILEX AG. WILEX AG will be eligible for single-digit royalties on net sales of the HER-2/neu and CAIX assays. Nuclea and WILEX AG have also signed a development agreement under which Nuclea will develop an automated CAIX IVD IHC assay, for which Nuclea will bear development costs. Under the agreement, distribution and marketing agreements for the marketed Oncogene Science tests will be transferred to Nuclea, which will acquire the GMP facility in Cambridge.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.